We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Cancer has a diagnostic and therapeutic complexity that makes the multidisciplinary approach of its treatment essential
We base oncology care on three pillars: our professionals, equipment and clinical research
In recent years, Vall d’Hebron has received some of the most prestigious recognitions in the field of cancer patient care.
As a result of its significant growth across its clinical, research and teaching activity, it was recognised as a Comprehensive Cancer Centre in 2023. This accreditation recognises excellence in comprehensive cancer care, including prevention, early diagnosis, treatment, patient follow-up and palliative care. The evaluation is holistic and covers clinical care, research and teaching, both in undergraduate medical and nursing training. Vall d’Hebron was the first centre in Spain to receive this accreditation. The process began in May 2021, when Vall d’Hebron was admitted as a member of the OECI, a non-governmental organisation founded in Vienna in 1979. The organisation currently includes more than 120 members, among them some of Europe’s leading comprehensive cancer centres. First, Vall d’Hebron completed a self-assessment process and submitted documentary evidence of its practices across nine key areas: governance, quality management systems, patient involvement, multidisciplinary care, cancer prevention and early detection, diagnosis, treatment, research, teaching and continuing education in oncology. In December 2021, an external team of auditors from the OECI visited Vall d’Hebron to conduct an onsite evaluation as a cancer centre. Finally, in 2023, the OECI granted Vall d’Hebron accreditation as a comprehensive cancer centre. We passed an external evaluation that accredited compliance with 85 standards and 343 sub-standards, both qualitative and quantitative, covering multidisciplinary integrated cancer care and research carried out through Vall d’Hebron University Hospital, the Vall d’Hebron Institute of Oncology (VHIO) and the Vall d’Hebron Research Institute (VHIR). In addition, Vall d’Hebron is the hospital in Spain with the highest number of CSUR (Reference Centres, Services and Units) accreditations for rare diseases, including certain types of cancer, and it participates in the largest number of European Reference Networks (ERNs).
In the late 1990s, around 800 new patients were seen each year in the Medical Oncology Department; today, that figure is approximately 7,000. As the hospital is a referral centre for the whole of Spain, 60% of the patients treated in the Department come from outside its reference area. Some patients are referred from the outset, particularly those with rare diseases. Others, with more common conditions, arrive after previous treatments have failed when Vall d’Hebron can offer more experimental options. Since the Department was first established, many things have changed. In the area of drug development, targeted therapies have been designed to act on specific genetic alterations in tumours; immunotherapy, which stimulates the immune system to fight the disease; and other more recent treatments that are still under investigation. All of these are helping to improve patient survival. The revolution in diagnostics has also contributed to improved outcomes. Until the 1990s, the diagnosis was purely pathological (staining to determine the type of tumour). This was followed by the genomic revolution, first with the sequencing of the human genome and later the tumour genome. These advances have gradually been incorporated into clinical practice, and genomic panels are now used in Catalonia to detect genetic alterations in specific diseases using NGS (next-generation sequencing) technology. In 2024, liquid biopsy was introduced for the diagnosis of certain subtypes of lung cancer.
As the Hospital is a referral centre for the whole of Spain, 60% of the patients treated in the Department come from outside its reference area.
La Vanguardia interviews Dr. Josep Tabernero Read the interview
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.